THC Global Group Limited (ASX:THC) Smart thinking on cannabis Investor Presentation June 2020 THC GLOBAL GROUP LIMITED (ASX:THC) 1
Australia’s newest Launched Affordable Medicines Range pharmaceutical company - delivered Acquired Clinics to Increase Accessibility Own Australian Bio-Pharma Factory Complete GMP Certification (EU and TGA) Established Export Channels Achieved Dominant Market Position Launched Global Scale Medicines Supply Positioned to Lead Pharma OTC Secured Upstream Cannabis Supply THC GLOBAL GROUP LIMITED (ASX:THC) 2
Delivering in World Class Pharma Global Supply of Four Core Areas Production Medicines Four interconnected revenue centres addressing major global barriers to industry growth Direct Patient Turnkey Cultivation Healthcare Services Solutions THC GLOBAL GROUP LIMITED (ASX:THC) 3
Pharma Production Made World Class TGA & EU GMP Licenced Scalable Production Pharma GMP cannabis medicines Production capacity scalable up to production with full EU compliance 1 million patients per annum with enabling export opportunities. limited additional capex. Finished Goods Diversity Onsite R&D Lab Developing capability for Onsite labs enables product testing production of capsules, tablets, and validation in addition to creams and other finished production required for product forms. clinical trials. Reliable Supply Secured White Label & Own Lines Access to own cultivation facilities Ability to service high volume bulk in addition to local Aust growers, processing or white-labelled orders and crude extract imports. without limiting own production. THC GLOBAL GROUP LIMITED (ASX:THC) 4
Pharma Production at Global Scale THC Global Cultivation Sites Canndeo Branded Medicines Third Party Australian Growers Third Party Brands International Raw Crude Pharmaceutical API THC GLOBAL GROUP LIMITED (ASX:THC) 5
Affordable and Accessible Medicines Canndeo THC GLOBAL GROUP LIMITED (ASX:THC) 6
Opening Australia’s Prescribing Market SAS-B Approvals 10000 9000 Solving the 8000 Affordability & 7000 6000 Accessibility Gap 5000 Tetra Health 4000 3000 2000 1000 0 Apr-19 May-19 Jun-19 Jul-19 Aug-19 Sep-19 Oct-19 Feb-20 Mar-20 Apr-20 Nov-19 Dec-19 Jan-20 CanndeoCare THC GLOBAL GROUP LIMITED (ASX:THC) 7
Order of Magnitude $200m+ Addressable Capturing the Volume Increase Patient Market New Pharma OTC Market Unprecedented opportunity to dominate a new $200m+ market White Label Canndeo Branded Medicines Opportunity THC GLOBAL GROUP LIMITED (ASX:THC) 8
Exporting to Global Markets Delivering a global supply of 2020 affordable quality medicines 2021+ THC GLOBAL GROUP LIMITED (ASX:THC) 9
Smart Businesses for the Canadian Market High growth businesses developed for the Canadian market with strong profitability potential Turnkey Cultivation Solutions Medicinal Cannabis THC GLOBAL GROUP LIMITED (ASX:THC) 10
Global Management Team Steven Xu Ken Charteris Jarrod White Andrew Beehag Laura Harvey Angela Macquire Diandra Phipps Sonny Didugu THC GLOBAL GROUP LIMITED (ASX:THC) 11
Capital and Financial Overview Key Information Recent Financials ASX Code ASX:THC Cash $2.26 million + $4m debt facility (31 March) Listing Date May 2017 Property Plant and $18.4 million Equipment (2019) Pharmaceuticals, Biotechnology GICS Classification & Life Science $4 million secured debt facility Existing Debt repayable 31 October 2021 Share Price $0.44 (3 June) 2019 Group Revenue $4.79 million Market Cap $64.25 million 55% YoY (2018-19) (3 June) Revenue Growth 44% YoY on Q1 Cash Receipts Shares on Issue 146,028,486 (3 June) Shareholders 8,888 Shareholders (3 June) THC GLOBAL GROUP LIMITED (ASX:THC) 12
Disclaimer THC GLOBAL GROUP LIMITED (ASX:THC) 13
C O R P O R A T E O F F I C E Suite 4102 Level 41 Australia Square CONTACT 264-278 George Street Sydney NSW 2000 THC GLOBAL GROUP Australia ASX:THC E M A I L corporate@thc.global W E B thc.global THC GLOBAL GROUP LIMITED (ASX:THC) 14
Recommend
More recommend
